Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

- PMLiVE

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

- PMLiVE

New drugs can’t keep Novartis sales on the up

Total group sales down 1% despite Cosentyx profit

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

- PMLiVE

Novartis gets lung cancer OK for Tafinlar/Mekinist combo

It can now be used to treat BRAF V600E-positive NSCLC patients in Europe

Novartis day

Novartis files CAR-T therapy in US, with swift review

CTL109 candidate gets FDA priority review status

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

Novartis day

What future for serelaxin after phase III miss?

Novartis' acute heart failure therapy misses two main endpoints

- PMLiVE

Novartis appoints new UK managing director

Haseeb Ahmad joins the firm from MSD

Novartis day

Could Cosentyx free psoriasis patients from treatment?

One in five patients on the Novartis treatment remained symptom-free for a year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links